6,7-dimethyl-8-ribityllumazine synthase (LS)

6,7-dimethyl-8-ribityllumazine synthase (LS) is an essential enzyme in the riboflavin (vitamin B2) biosynthetic pathway, found in bacteria, fungi, and plants but notably absent in humans [1, 5]. It catalyzes the penultimate step of the pathway, specifically the condensation of 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione with 3,4-dihydroxy-2-butanone 4-phosphate to produce 6,7-dimethyl-8-ribityllumazine [1, 2]. Since humans lack the ability to synthesize riboflavin and must acquire it through diet, LS represents a highly selective target for the development of novel antimicrobial and antifungal agents [7, 12]. Inhibition of this enzyme disrupts the production of essential flavin cofactors (FMN and FAD), leading to the cessation of microbial growth and survival [5, 20]. Research has identified several potent inhibitors, including lumazine and purine analogues, which act as competitive inhibitors at the enzyme's active site [7, 10]. Beyond its role as a drug target, the unique icosahedral or pentameric assembly of LS has made it a valuable tool in biotechnology for vaccine development and as a scaffold for nanoparticle-based drug delivery [19]. The enzyme's high stability and well-defined structure facilitate the design of specific inhibitors that can overcome drug resistance in pathogenic strains [7, 15]. Therapeutic challenges include ensuring effective delivery to intracellular pathogens and minimizing potential impacts on the host's commensal microbiome [16, 20].

Other names

Lumazine synthaseDMRL synthaseRibHRIB4RibEHeavy riboflavin synthase beta subunit

Competitive inhibition of the enzyme's active site, blocking the condensation of 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione and 3,4-dihydroxy-2-butanone 4-phosphate, thereby halting riboflavin biosynthesis and subsequent production of FMN and FAD cofactors [5, 7, 13].